{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:40:11Z","timestamp":1742438411943,"version":"3.40.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018779","name":"Milner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108534","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T23:43:16Z","timestamp":1720568596000},"page":"108534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients with Gaucher disease display systemic elevation of ACE2, which is impacted by therapy status and genotype"],"prefix":"10.1016","volume":"143","author":[{"given":"Ahmad","family":"Fokra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit Baris","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Kurolap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Kinaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Abassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tova","family":"Hershkovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2024.108534_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108534_bb0010","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J","article-title":"Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population","volume":"12","author":"Horowitz","year":"1998","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108534_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease - diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2024.108534_bb0025","series-title":"The Metabolic and Molecular Basis of Inherited disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"issue":"4857","key":"10.1016\/j.ymgme.2024.108534_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/bmj.1.4857.290","article-title":"Protection afforded by sickle-cell trait against subtertian malarial infection","volume":"1","author":"Allison","year":"1954","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrg3734","article-title":"Natural selection and infectious disease in human populations","volume":"15","author":"Karlsson","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108534_bb0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.tree.2012.08.012","article-title":"What is the evidence for heterozygote advantage selection?","volume":"27","author":"Hedrick","year":"2012","journal-title":"Trends Ecol. Evol."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108534_bb0045","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/imj.14894","article-title":"Impact of Gaucher disease on COVID-19","volume":"50","author":"Zimran","year":"2020","journal-title":"Intern. Med. J."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108534_bb0050","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/bjh.17693","article-title":"Experts\u2019 views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease","volume":"195","author":"Hamiel","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2021.02.005","article-title":"Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown","volume":"132","author":"Ginns","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108534_bb0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2020.04.002","article-title":"Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience","volume":"130","author":"Sechi","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/a-1821-9009","article-title":"Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic","volume":"61","author":"Niederau","year":"2023","journal-title":"Z. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108534_bb0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2021.08.004","article-title":"The clinical spectrum of SARS-CoV-2 infection in Gaucher disease\u00a0: effect of both a pandemic and a rare disease that disrupts the immune system","volume":"135","author":"Narayanan","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108534_bb0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/imj.15673","article-title":"No association of Gaucher disease with COVID-19-related outcomes: a nationwide cohort study","volume":"52","author":"Demirci","year":"2022","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ymgme.2024.108534_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.96","article-title":"Pre-existing humoral immune comebacks control the development of the severe form of coronavirus disease 2019 in Gaucher patients","volume":"2","author":"Pandey","year":"2022","journal-title":"Clin. Transl. Discov."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108534_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2020.12.288","article-title":"Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York","volume":"132","author":"Fierro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108534_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2021.08.004","article-title":"The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: effect of both a pandemic and a rare disease that disrupts the immune system","volume":"135","author":"Narayanan","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0095","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.cell.2020.10.039","article-title":"\u03b2-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway","volume":"183","author":"Ghosh","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108534_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10224","key":"10.1016\/j.ymgme.2024.108534_bb0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0110","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1096\/fj.202000654R","article-title":"The lysosome: a potential juncture between SARS-CoV-2 infectivity and Niemann-pick disease type C, with therapeutic implications","volume":"34","author":"Ballout","year":"2020","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ymgme.2018.02.007","article-title":"ACE phenotyping in Gaucher disease","volume":"123","author":"Danilov","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10545-005-0585-9","article-title":"Evaluation of three biochemical markers in the monitoring of Gaucher disease","volume":"28","author":"Vellodi","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108534_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/imm.13125","article-title":"Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro","volume":"159","author":"Nielsen","year":"2020","journal-title":"Immunology"},{"issue":"112","key":"10.1016\/j.ymgme.2024.108534_bb0130","first-page":"6","article-title":"Culture of macrophage colony-stimulating factor differentiated human monocyte-derived macrophages","volume":"2016","author":"Jin","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108534_bb0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217673120","article-title":"Gaucher disease protects against tuberculosis","volume":"120","author":"Fan","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymgme.2024.108534_bb0140","first-page":"11","article-title":"ACE2, COVID-19 infection, inflammation, and coagulopathy: missing pieces in the puzzle","author":"Abassi","year":"2020","journal-title":"Front. Physiol."},{"issue":"June","key":"10.1016\/j.ymgme.2024.108534_bb0145","first-page":"1","article-title":"The lung macrophage in SARS-CoV-2 infection: a friend or a foe?","volume":"11","author":"Abassi","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0150","doi-asserted-by":"crossref","first-page":"E878","DOI":"10.1152\/ajpendo.00183.2020","article-title":"Is there an impact of the COVID-19 pandemic on male fertility? The ACE2 connection","volume":"318","author":"Youni","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108534_bb0155","doi-asserted-by":"crossref","first-page":"H1080","DOI":"10.1152\/ajpheart.00215.2020","article-title":"Letter to the editor: angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications","volume":"318","author":"Abassi","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108534_bb0160","first-page":"L1020","article-title":"Covid-19 infection and mortality: a physiologist\u2019s perspective enlightening clinical features and plausible interventional strategies","volume":"318","author":"Abassi","year":"2020","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"43","key":"10.1016\/j.ymgme.2024.108534_bb0165","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem [Internet]"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108534_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2024.108534_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cca.2021.10.029","article-title":"Angiotensin converting enzyme (ACE)","volume":"524","author":"Khurana","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0180","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108534_bb0185","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 anti type 3 gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108534_bb0190","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jmv.25785","article-title":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19","volume":"92","author":"Cheng","year":"2020","journal-title":"J. Med. Virol."},{"issue":"January","key":"10.1016\/j.ymgme.2024.108534_bb0195","first-page":"1","article-title":"ACE2 shedding and the role in COVID-19","volume":"11","author":"Wang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymgme.2024.108534_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170766","article-title":"Angiotensin-converting enzyme 2 (ACE2): two decades of revelations and re-evaluation","volume":"151","author":"Turner","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.ymgme.2024.108534_bb0205","doi-asserted-by":"crossref","unstructured":"F. Golab, G. Vahabzadeh, L. Sadeghroudbari, A. Shirazi, R. Shabani, S. Tanbakooei, et al., The protective potential role of ACE2 against COVID-19, Adv. Virol. vol. 2023 online(2023).","DOI":"10.1155\/2023\/8451931"},{"issue":"5","key":"10.1016\/j.ymgme.2024.108534_bb0210","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/HYPERTENSIONAHA.120.15948","article-title":"Severe acute respiratory syndrome coronavirus 2, COVID-19, and the renin-angiotensin system: pressing needs and best research practices","volume":"76","author":"Sparks","year":"2020","journal-title":"Hypertension"},{"issue":"17","key":"10.1016\/j.ymgme.2024.108534_bb0215","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem [Internet]"},{"key":"10.1016\/j.ymgme.2024.108534_bb0220","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijid.2020.11.184","article-title":"A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient","volume":"103","author":"Nagy","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108534_bb0225","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.ymgme.2024.108534_bb0230","doi-asserted-by":"crossref","first-page":"16646","DOI":"10.1021\/acs.jmedchem.3c01201","article-title":"Protective efficacy of novel engineered human ACE2-fc Fusion protein against Pan-SARS-CoV-2 infection in vitro and in vivo","volume":"66","author":"Yu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymgme.2024.108534_bb0235","doi-asserted-by":"crossref","unstructured":"D.L. Kober, M.C. Caballero Van Dyke, J.L. Eitson, I.N. Boys, McDougal MB, D.M. Rosenbaum, et al., Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo, mBio. 2024 online Jun; 15(6).","DOI":"10.1128\/mbio.00768-24"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:19:49Z","timestamp":1742437189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004189"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108534","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with Gaucher disease display systemic elevation of ACE2, which is impacted by therapy status and genotype","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108534"}}